<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02527564</url>
  </required_header>
  <id_info>
    <org_study_id>53208</org_study_id>
    <nct_id>NCT02527564</nct_id>
  </id_info>
  <brief_title>Efficacy of Suvorexant to Treat Insomnia Related to Bipolar Disorder</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled Trial of Adjunctive Suvorexant for Treatment-resistant Insomnia in Patients With Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of suvorexant, added to existing
      medications, for treatment-resistant insomnia in individuals with bipolar disorder. The
      investigators hypothesize that participants receiving suvorexant for one week will experience
      significantly greater improvement in sleep duration compared to participants receiving
      placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be randomized to receive double-blind suvorexant or placebo for one week,
      after which all participants will receive open treatment with suvorexant for three months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>subjective total sleep time - acute</measure>
    <time_frame>week 1 of double-blind, placebo-controlled phase</time_frame>
    <description>measured by self-report electronic sleep diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective total sleep time - acute</measure>
    <time_frame>week 1 of double-blind, placebo-controlled phase</time_frame>
    <description>measured by actigraphy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>subjective total sleep time - subchronic</measure>
    <time_frame>month 1, month 2, and month 3 of open treatment phase</time_frame>
    <description>measured by self-report electronic sleep diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective total sleep time - subchronic</measure>
    <time_frame>month 1, month 2, and month 3 of open treatment phase</time_frame>
    <description>measured by actigraphy</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Insomnia</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Suvorexant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50% of enrolled participants will be randomly assigned to receive double-blind suvorexant for one week, dosed at 10mg every bedtime for the first 3 nights, then increased to 20mg every bedtime for the last 4 nights.
Following the one-week double-blind, placebo-controlled phase, 100% of participants will receive open-label suvorexant for 3 months, dosed at 10mg every bedtime for the first 3 nights, then increased to 20mg every bedtime for the remainder of 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50% of enrolled participants will be randomly assigned to receive double-blind placebo pill for one week, dosed at 10mg every bedtime for the first 3 nights, then increased to 20mg every bedtime for the last 4 nights.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suvorexant</intervention_name>
    <arm_group_label>Suvorexant</arm_group_label>
    <other_name>Belsomra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult outpatients meeting Diagnostic and Statistical Manual of Mental Disorders,
             Fourth Edition, Text Revision (DSM-IV-TR) criteria for bipolar I disorder (296.70),
             bipolar II disorder (296.89), or bipolar disorder not otherwise specified (296.80),
             with concurrent insomnia related to bipolar disorder (307.42).

          2. Currently taking ≥ 1 prescription psychotropic medication (hypnotic agents,
             anxiolytics, atypical antipsychotics, mood stabilizers, and/or antidepressants) for
             management of bipolar disorder.

          3. Subjective total sleep time (sTST) &lt; 6 hours on ≥ 1 night during the prior week.

        Exclusion Criteria:

          1. Current hypo/manic symptoms, as evidenced by YMRS total score ≥ 12.

          2. Current (past 6 months) alcohol or substance use disorder.

          3. Current psychosis.

          4. Patients who are actively suicidal or evaluated as being a high suicide risk.

          5. Women who are currently pregnant or breastfeeding.

          6. Clinically significant abnormalities on baseline laboratory tests (comprehensive
             metabolic panel, fasting lipid panel, CBC with differential, thyroid stimulating
             hormone).

          7. Presence of any unstable and/or potentially confounding neurological and/or medical
             disorder.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shefali Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauren Chang, B.S.</last_name>
    <phone>650-498-8459</phone>
    <email>laurensc@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Chang, B.S.</last_name>
      <phone>650-498-8459</phone>
      <email>laurensc@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2015</study_first_submitted>
  <study_first_submitted_qc>August 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <last_update_submitted>October 3, 2017</last_update_submitted>
  <last_update_submitted_qc>October 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Shefali Miller</investigator_full_name>
    <investigator_title>Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
    <mesh_term>Sleep Initiation and Maintenance Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suvorexant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

